Item 2.02 Results of Operations and Financial Condition

On November 16, 2020, Windtree Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure

On November 16, 2020, the Company released an investor presentation to be used in presentations to investors from time to time. A copy of this investor presentation is attached hereto as Exhibit 99.2.

The information contained in each of Item 2.02 (including Exhibit 99.1) and Item 7.01 (including Exhibit 99.2) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits





(d) Exhibits



Exhibit
No.                                       Document

99.1         Press Release of Windtree Therapeutics, Inc., dated November 16,
           2020, announcing financial results for the quarter ended September 30,
           2020, furnished herewith.
99.2         Windtree Therapeutics, Inc. Investor Presentation

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses